Hermann-Josef Rothkötter Selected Research

deoxynivalenol

1/2021	Does chronic dietary exposure to the mycotoxin deoxynivalenol affect the porcine hepatic transcriptome when an acute-phase response is initiated through first or second-pass LPS challenge of the liver?
11/2020	Oral exposure of pigs to the mycotoxin deoxynivalenol does not modulate the hepatic albumin synthesis during a LPS-induced acute-phase reaction.
1/2019	Effects of deoxynivalenol-feed contamination on circulating LPS in pigs.
11/2018	Deoxynivalenol Affects Cell Metabolism and Increases Protein Biosynthesis in Intestinal Porcine Epithelial Cells (IPEC-J2): DON Increases Protein Biosynthesis.
12/2015	Does Dietary Deoxynivalenol Modulate the Acute Phase Reaction in Endotoxaemic Pigs?--Lessons from Clinical Signs, White Blood Cell Counts, and TNF-Alpha.
11/2015	Metabolic and hematological consequences of dietary deoxynivalenol interacting with systemic Escherichia coli lipopolysaccharide.
2/2015	Systemic E. coli lipopolysaccharide but not deoxynivalenol results in transient leukopenia and diminished metabolic activity of peripheral blood mononuclear cells ex vivo.
7/2013	The Fusarium toxin deoxynivalenol (DON) modulates the LPS induced acute phase reaction in pigs.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hermann-Josef Rothkötter Research Topics

Disease

4	Inflammation (Inflammations) 01/2021 - 12/2012
4	Acute-Phase Reaction 01/2021 - 07/2013
3	Body Weight (Weight, Body) 06/2018 - 02/2015
2	Neoplasms (Cancer) 01/2018 - 12/2015
2	Leukopenia 12/2015 - 02/2015
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2021
1	Septic Shock (Toxic Shock Syndrome) 01/2019
1	Vomiting 11/2018
1	Colorectal Neoplasms (Colorectal Cancer) 01/2018
1	Stroke (Strokes) 01/2018
1	Hyperthermia 12/2015
1	Melanoma (Melanoma, Malignant) 12/2015
1	Lactic Acidosis 11/2015
1	Infections 09/2013
1	Food Hypersensitivity (Food Allergy) 11/2012
1	Hypersensitivity (Allergy) 11/2012
1	Necrosis 02/2011
1	Communicable Diseases (Infectious Diseases) 02/2009
1	Arteriosclerosis 07/2002

Drug/Important Bio-Agent (IBA)

8	deoxynivalenolIBA 01/2021 - 07/2013
5	MycotoxinsIBA 01/2021 - 02/2015
3	Proteins (Proteins, Gene)FDA Link 01/2021 - 11/2012
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 12/2015 - 07/2013
2	AntigensIBA 12/2015 - 11/2012
2	LipopolysaccharidesIBA 11/2015 - 02/2015
1	AlbuminsIBA 11/2020
1	Saline SolutionIBA 06/2018
1	Dacarbazine (DIC)FDA LinkGeneric 01/2018
1	SolutionsIBA 08/2017
1	AminopeptidasesIBA 12/2015
1	EpitopesIBA 12/2015
1	Differentiation AntigensIBA 12/2015
1	Peptides (Polypeptides)IBA 12/2015
1	Proteasome Endopeptidase Complex (Proteasome)IBA 12/2015
1	MART-1 AntigenIBA 12/2015
1	Lactic Acid (Lactate)FDA LinkGeneric 11/2015
1	EndotoxinsIBA 02/2015
1	Calmodulin (Calcium-Dependent Activator Protein)IBA 09/2013
1	NF-kappaB-Inducing KinaseIBA 09/2013
1	Phosphotransferases (Kinase)IBA 09/2013
1	Interleukin-6 (Interleukin 6)IBA 07/2013
1	CytokinesIBA 07/2013
1	BilirubinIBA 12/2012
1	Caspase 3 (Caspase-3)IBA 02/2011
1	scleroglucanIBA 02/2009
1	Angiotensin IIIBA 07/2002

Therapy/Procedure

3	Catheters 08/2017 - 02/2015
1	Therapeutics 01/2018
1	Immunotherapy 12/2015